763 related articles for article (PubMed ID: 8751438)
21. [Oxidative stress, beta-amyloide peptide and Alzheimer's disease].
Manzano-León N; Mas-Oliva J
Gac Med Mex; 2006; 142(3):229-38. PubMed ID: 16875352
[TBL] [Abstract][Full Text] [Related]
22. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease.
Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
Med Hypotheses; 2005; 64(6):1205-7. PubMed ID: 15823718
[TBL] [Abstract][Full Text] [Related]
23. Alzheimer's disease. Amyloid ox-tox transducers.
Mattson MP; Rydel RE
Nature; 1996 Aug; 382(6593):674-5. PubMed ID: 8751434
[No Abstract] [Full Text] [Related]
24. Alzheimer's amyloid beta-peptide (1-42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide.
Butterfield DA; Bush AI
Neurobiol Aging; 2004; 25(5):563-8. PubMed ID: 15172731
[TBL] [Abstract][Full Text] [Related]
25. In vivo conversion of racemized beta-amyloid ([D-Ser 26]A beta 1-40) to truncated and toxic fragments ([D-Ser 26]A beta 25-35/40) and fragment presence in the brains of Alzheimer's patients.
Kubo T; Nishimura S; Kumagae Y; Kaneko I
J Neurosci Res; 2002 Nov; 70(3):474-83. PubMed ID: 12391608
[TBL] [Abstract][Full Text] [Related]
26. Amyloid beta interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease.
Lorenzo A; Yuan M; Zhang Z; Paganetti PA; Sturchler-Pierrat C; Staufenbiel M; Mautino J; Vigo FS; Sommer B; Yankner BA
Nat Neurosci; 2000 May; 3(5):460-4. PubMed ID: 10769385
[TBL] [Abstract][Full Text] [Related]
27. Possible role of scavenger receptor SRCL in the clearance of amyloid-beta in Alzheimer's disease.
Nakamura K; Ohya W; Funakoshi H; Sakaguchi G; Kato A; Takeda M; Kudo T; Nakamura T
J Neurosci Res; 2006 Sep; 84(4):874-90. PubMed ID: 16868960
[TBL] [Abstract][Full Text] [Related]
28. Sublethal concentrations of prion peptide PrP106-126 or the amyloid beta peptide of Alzheimer's disease activates expression of proapoptotic markers in primary cortical neurons.
White AR; Guirguis R; Brazier MW; Jobling MF; Hill AF; Beyreuther K; Barrow CJ; Masters CL; Collins SJ; Cappai R
Neurobiol Dis; 2001 Apr; 8(2):299-316. PubMed ID: 11300725
[TBL] [Abstract][Full Text] [Related]
29. The Alzheimer's A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice.
LaFerla FM; Tinkle BT; Bieberich CJ; Haudenschild CC; Jay G
Nat Genet; 1995 Jan; 9(1):21-30. PubMed ID: 7704018
[TBL] [Abstract][Full Text] [Related]
30. Oxidative stress in vascular dementia and Alzheimer's disease: a common pathology.
Bennett S; Grant MM; Aldred S
J Alzheimers Dis; 2009; 17(2):245-57. PubMed ID: 19221412
[TBL] [Abstract][Full Text] [Related]
31. Advanced glycation end products are mitogenic signals and trigger cell cycle reentry of neurons in Alzheimer's disease brain.
Kuhla A; Ludwig SC; Kuhla B; Münch G; Vollmar B
Neurobiol Aging; 2015 Feb; 36(2):753-61. PubMed ID: 25448604
[TBL] [Abstract][Full Text] [Related]
32. Amyloid beta peptides and central cholinergic neurons: functional interrelationship and relevance to Alzheimer's disease pathology.
Kar S; Quirion R
Prog Brain Res; 2004; 145():261-74. PubMed ID: 14650921
[No Abstract] [Full Text] [Related]
33. Two β-strands of RAGE participate in the recognition and transport of amyloid-β peptide across the blood brain barrier.
Kim SJ; Ahn JW; Kim H; Ha HJ; Lee SW; Kim HK; Lee S; Hong HS; Kim YH; Choi CY
Biochem Biophys Res Commun; 2013 Sep; 439(2):252-7. PubMed ID: 23973487
[TBL] [Abstract][Full Text] [Related]
34. RAGE is a key cellular target for Abeta-induced perturbation in Alzheimer's disease.
Yan SS; Chen D; Yan S; Guo L; Du H; Chen JX
Front Biosci (Schol Ed); 2012 Jan; 4(1):240-50. PubMed ID: 22202057
[TBL] [Abstract][Full Text] [Related]
35. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease.
Lue LF; Yan SD; Stern DM; Walker DG
Curr Drug Targets CNS Neurol Disord; 2005 Jun; 4(3):249-66. PubMed ID: 15975028
[TBL] [Abstract][Full Text] [Related]
36. Vascular factors in diabetes and Alzheimer's disease.
Taguchi A
J Alzheimers Dis; 2009; 16(4):859-64. PubMed ID: 19387118
[TBL] [Abstract][Full Text] [Related]
37. Cytotoxic role of advanced glycation end-products in PC12 cells treated with β‑amyloid peptide.
Yan FL; Han GL; Wu GJ
Mol Med Rep; 2013 Aug; 8(2):367-72. PubMed ID: 23799541
[TBL] [Abstract][Full Text] [Related]
38. Role of RAGE in Alzheimer's Disease.
Cai Z; Liu N; Wang C; Qin B; Zhou Y; Xiao M; Chang L; Yan LJ; Zhao B
Cell Mol Neurobiol; 2016 May; 36(4):483-95. PubMed ID: 26175217
[TBL] [Abstract][Full Text] [Related]
39. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice.
Arancio O; Zhang HP; Chen X; Lin C; Trinchese F; Puzzo D; Liu S; Hegde A; Yan SF; Stern A; Luddy JS; Lue LF; Walker DG; Roher A; Buttini M; Mucke L; Li W; Schmidt AM; Kindy M; Hyslop PA; Stern DM; Du Yan SS
EMBO J; 2004 Oct; 23(20):4096-105. PubMed ID: 15457210
[TBL] [Abstract][Full Text] [Related]
40. Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease.
Takeuchi M; Yamagishi S
J Alzheimers Dis; 2009; 16(4):845-58. PubMed ID: 19387117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
